3 ms·
http://www.bloomberg.com/news/2013-06-13/the-supreme-court-s-bad-science-on-gene-patents.html http://www.bloomberg.com/news/2013-06-13/the-supreme-court-s... i
by acqq 13y ago
http://www.bloomberg.com/news/2013-06-13/the-supreme-court-s-bad-science-on-gene-patents.html http://www.bloomberg.com/news/2013-06-13/the-supreme-court-s...
it is not the scientists who removed the introns from the officially unpatentable original DNA sequence to make the new, patentable cDNA sequence. It is nature itself, through the magic by which pre-RNA, which includes the introns, becomes messenger RNA, which does not. The Supreme Court described this process by saying, “the pre-RNA is then naturally ‘spliced’ by the physical removal of the introns” -- that is, the introns are removed as part of the ordinary process by which messenger RNA is created. The role scientists then subsequently play is to take the messenger RNA and use it to synthesize the intron-free cDNA.
To put it much more simply, there is nothing that a 6-year-old would consider “invented” about the patentable cDNA. It is nothing more than the messenger RNA flipped into a DNA sequence that omits unnecessary elements that nature already excluded. The sequence that codes the proteins is just as naturally occurring as the original DNA itself, which the court held couldn’t be patented because it was naturally occurring. The distinction is, to put it bluntly, a lawyer’s distinction, not a scientist’s.
(by Noah Feldman, a professor of constitutional and international law at Harvard)
- daughart 13y agoFrom what I understand, Myriad's test involved synthesis of cDNA (which we scientists refer to as "complementary DNA", not "composite DNA" as SCOTUS does). This is still covered by the patent. However, any test based on sequencing the genomic DNA, for example, would not violate Myriad's patent. Genomic sequencing of these genes was previously a violation of the patent. This is definitely a step forward. In the long run, Myriad is hosed because they no longer own the sequence, including analysis. Any diagnostic not using reverse transcription of the mRNA does not violate Myriad's patent. This includes synthesis of any non-cDNA polymer, such as XNA.
- alsocasey 13y agoThe issue is that a hypothetical diagnostic attempting to sequence this region would likely be pre-processed with a PCR to facilitate sequencing of only the region of interest... this necessarily involves a cDNA step. You could sequence the whole genome at higher depth, but this would be more expensive. Edit: My mistake, the patent covers the reverse transcription step exclusively, not the act of transcription in general - which means PCR from genomic DNA is fine, but rtPCR or cDNA library construction is not... no scientific consistency there, but looks like cheaper BCRA tests in the near future.
- daughart 13y agoPCR is not covered by the patent, only reverse transcription of the processed RNA molecule to cDNA. There are many flavors of genomic PCR that are fine under this interpretation, including a rapid SNP-detecting digital qPCR.
- deleted 13y ago[deleted]
- HarryHirsch 13y ago> To put it much more simply, there is nothing that a 6-year-old would consider “invented” about the patentable cDNA. That's the point. Patent law is very suitable for processes that cost millions to develop, but in pharmaceutics the big cost factor isn't process development, it is the discovery. What Myriad did is identify the gene, that is where the cost was sunk that they somehow have to recover. But since you can patent only things, and not intellectual property, the Supreme Court had to resort to all kinds of legal hacks of the sort that judges hate to see applied in their courtroom.
- jamesjporter 13y agoSaying that Myriad was the first to discover BRCA1 is somewhat disingenuous; other labs did it independently at roughly the same time. Moreover, deciding when a gene was "discovered" is a minefield. What constitues discovery? Identification of a mutant? Cloning the gene? Sequencing it? There are many steps to this process.
- HarryHirsch 13y agoYou'd say that correlating certain mutations in the gene to increased risk of breast cancer constitutes discovery, it certainly does in the context of a clinical test for breast cancer, which is what Myriad is selling.